Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study

Ford, 2005, Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. A summary of the evidence, Diabetes Care, 28, 1769, 10.2337/diacare.28.7.1769 Metascreen Writing Committee, 2006, The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey, Diabetes Care, 29, 2701, 10.2337/dc06-0942 Bonora, 2004, The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study, Diabet Med, 21, 52, 10.1046/j.1464-5491.2003.01068.x Alexander, 2003, NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older, Diabetes, 52, 1210, 10.2337/diabetes.52.5.1210 Bianchi, 2008, Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome, Nutr Metab Cardiovasc Dis, 18, 31, 10.1016/j.numecd.2006.07.007 Lorenzo, 2003, The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study, Diabetes Care, 26, 3153, 10.2337/diacare.26.11.3153 Stern, 2004, Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?, Diabetes Care, 27, 2676, 10.2337/diacare.27.11.2676 Bhargava, 2003, A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study, Popul Health Metr, 1, 3, 10.1186/1478-7954-1-3 Isomaa, 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 24, 683, 10.2337/diacare.24.4.683 Lakka, 2002, The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 288, 2709, 10.1001/jama.288.21.2709 Sattar, 2003, Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study, Circulation, 108, 414, 10.1161/01.CIR.0000080897.52664.94 Girman, 2004, The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), Am J Cardiol, 93, 136, 10.1016/j.amjcard.2003.09.028 Reaven, 1988, Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 37, 1595, 10.2337/diabetes.37.12.1595 Ferrannini, 1991, Hyperinsulinaemia: key future of cardiovascular and metabolic syndrome, Diabetologia, 34, 416, 10.1007/BF00403180 Bonora, 2007, Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study, Diabetes Care, 30, 318, 10.2337/dc06-0919 Rhee, 2007, Insulin secretion and insulin resistance in newly diagnosed, drug naive prediabetes and type 2 diabetes patients with/without metabolic syndrome, Diabetes Res Clin Pract, 76, 397, 10.1016/j.diabres.2006.09.035 1997, Report of the expert committee on the diagnosis and classification of diabetes mellitus, Diabetes Care, 20, 1183, 10.2337/diacare.20.7.1183 2001, JAMA, 285, 2486, 10.1001/jama.285.19.2486 Alberti, 2005, The metabolic syndrome-a new worldwide definition, Lancet, 366, 1059, 10.1016/S0140-6736(05)67402-8 Alberti, 2009, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 Matthews, 1985, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883 Tura, 2006, Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT, Diabetes Res Clin Pract, 72, 298, 10.1016/j.diabres.2005.10.005 Bonora, 1998, Prevalence of insulin resistance in metabolic disorders: the Bruneck study, Diabetes, 47, 1643, 10.2337/diabetes.47.10.1643 Novoa, 2005, Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde study, Diabetes Care, 28, 2388, 10.2337/diacare.28.10.2388 Miccoli, 2005, Prevalence of the metabolic syndrome among Italian adults according to ATP III definition, Nutr Metab Cardiovasc Dis, 15, 250, 10.1016/j.numecd.2004.09.002 Tripathy, 2000, Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia study, Diabetes, 49, 975, 10.2337/diabetes.49.6.975 Ford, 2002, Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey, JAMA, 287, 356, 10.1001/jama.287.3.356 Rodriguez, 2005, Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore Longitudinal Study of Aging, Metabolism, 54, 542, 10.1016/j.metabol.2004.11.010 Kanauchi, 2006, Utility of elevated 2-hour postload plasma glucose as an alternative to elevated fasting glucose as a criterion for the metabolic syndrome, Metabolism, 55, 1323, 10.1016/j.metabol.2006.05.017 Mori, 2006, Japanese IGT subjects with high insulin response are far more frequently associated with the metabolic syndrome than those with low insulin response, Endocrine, 29, 351, 10.1385/ENDO:29:2:351 Warram, 1990, Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents, Ann Intern Med, 113, 909, 10.7326/0003-4819-113-12-909 Lillioja, 1993, Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians, N Engl J Med, 329, 1988, 10.1056/NEJM199312303292703 Yip, 1998, Resistance to insulin-medicated glucose disposal as a predictor of cardiovascular disease, J Clin Endocrinol Metab, 83, 2773, 10.1210/jc.83.8.2773 Davies, 2000, Impaired glucose tolerance and fasting hyperglycaemia have different characteristics, Diabet Med, 17, 433, 10.1046/j.1464-5491.2000.00246.x Carnevale Schianca, 2003, The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance, Diabetes Care, 26, 1333, 10.2337/diacare.26.5.1333 Williams, 2003, Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter?, Diabet Med, 20, 915, 10.1046/j.1464-5491.2003.01059.x Heldgaard, 2004, Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease, Diabet Med, 21, 363, 10.1111/j.1464-5491.2004.01231.x Hanefeld, 2000, Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD study, Diabet Med, 17, 835, 10.1046/j.1464-5491.2000.00408.x Haffner, 1999, Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study, Diabetes Care, 22, 562, 10.2337/diacare.22.4.562 Bonora, 2002, HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study, Diabetes Care, 25, 1135, 10.2337/diacare.25.7.1135 Hanley, 2002, Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis Study, Diabetes, 51, 2642, 10.2337/diabetes.51.8.2642 DeFronzo, 1991, Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease, Diabetes Care, 14, 173, 10.2337/diacare.14.3.173 Cruz, 2004, The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity, J Clin Endocrinol Metab, 89, 108, 10.1210/jc.2003-031188 Ferrannini, 1997, Insulin resistance and hypersecretion in obesity, J Clin Invest, 100, 1166, 10.1172/JCI119628 Cheal, 2004, Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome, Diabetes, 53, 1195, 10.2337/diabetes.53.5.1195 Després, 2006, Is visceral obesity the cause of the metabolic syndrome?, Ann Med, 38, 52, 10.1080/07853890500383895 Das, 2002, Is metabolic syndrome X an inflammatory condition?, Exp Biol Med (Maywood), 227, 989, 10.1177/153537020222701106 Saely, 2005, The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients, J Clin Endocrinol Metab, 90, 5698, 10.1210/jc.2005-0799 Reaven, 2004, Insulin resistance, cardiovascular disease, and the metabolic syndrome. How well do the emperor’s clothes fit?, Diabetes Care, 27, 1011, 10.2337/diacare.27.4.1011 Kahn, 2005, The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia, 48, 1684, 10.1007/s00125-005-1876-2 Liao, 2004, Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia, Diabetes Care, 27, 978, 10.2337/diacare.27.4.978 Sierra-Johnson, 2006, Correspondence between the adult treatment panel III criteria for metabolic syndrome and insulin resistance, Diabetes Care, 29, 668, 10.2337/diacare.29.03.06.dc05-0970